Outcomes of a 12-month course of early and late rituximab BCD020 biosimilar administration in juvenile systemic lupus erythematosus: A retrospective study

Figure 1 Study flow chart. ERA: Early rituximab administration; LRA: Late rituximab administration.

Figure 2 Outcomes after 12 months of treatment with early and late administration of rituximab BCD020 biosimilar. A: Dynamics of corticosteroids; B: Dynamics of Systemic Lupus Erythematosus Disease Activity Index. ERA: Early rituximab administration; LRA: Late rituximab administration.

Figure 3 Long-lasting treatment outcomes of rituximab BCD020 biosimilar with early and late administration. A: Probability of achieving low (≤ 0.2 mg/kg) corticosteroid dose in systemic lupus erythematosus patients with early and late rituximab administration; B: Probability of achieving remission (Systemic Lupus Erythematosus Disease Activity Index = 0) in systemic lupus erythematosus patients with early rituximab administration (ERA) and late rituximab administration (LRA).